JPRN-jRCTs031180362已完成未知
The efficacy of third or fourth line H. pylori eradication therapy with refabutin-amoxicillin-vonaprazan 7day regimen
Hirata Kenro0 个研究点目标入组 57 人开始时间: 2019年3月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 57
研究概览
简要总结
Seven-day low-dose RFB-based VAR therapy is effective and safe as a third- or later-line H. pylori eradication regimen.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •H. pylori-positve patients after the 2nd line H. pylori eradication therapy with informed consent
排除标准
- •1. Patients with allergy for rifamycins
- •2. Patients with past histry of tuberculosis or nontuberculous mycobacterial infection
- •3. Patients with allergy for PPIs
- •4. Patients with allergy for penicillin
- •5. Patients with severe liver injury and/or severe renal damage
- •6. Pregnancy or possible pregnancy
- •7. Patients who are taking voriconazole
- •8. Patients with uveitis
- •9. Patients who were recognized as inappropriate for entry
研究者
相似试验
已完成
4 期
Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential TherapyHelicobacter PyloriNCT05371249Fu Jen Catholic University Hospital628
已完成
不适用
Third line H. pylori eradication therapy with sitafloxacin, amoxicillin and vonaprazaHelicobacter pylori infectionJPRN-jRCTs031180413Hirata Kenro75
已完成
不适用
A retrospective study in clinical course of Heicobacter pylori eradication therapyH.pylori infected patientsJPRN-UMIN000032351Asahikawa Medical University427
已完成
3 期
The efficacy and safety of third line H. pylori eradication therapy with sitafloxacin, amoxicillin and PPIH. pylori-positve patients after the 2nd line eradication failureJPRN-UMIN000013194Keio University School of Medicine100
已完成
3 期
The efficacy and safety of third line H. pylori eradication therapy with sitafloxacin, metronidazole and PPIH. pylori-positve patients after the 2nd line eradication failure or penicillin-allergic patientsJPRN-UMIN000013195Keio University School of Medicine100